TLX INVESTOR ALERT: Telix Pharmaceuticals Ltd. Investors with Substantial Losses Have Opportunity to Lead the Telix Class Action Lawsuit - RGRD Law

Core Viewpoint - The Telix Pharmaceuticals class action lawsuit alleges that the company and its executives made false statements regarding the progress of prostate cancer therapeutic candidates and the quality of its supply chain, leading to significant stock price declines following negative disclosures [4][5][6]. Company Overview - Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals [3]. Allegations of the Lawsuit - The lawsuit claims that during the Class Period, Telix Pharmaceuticals materially overstated its progress in developing prostate cancer therapeutics and the quality of its supply chain [4]. - On July 22, 2025, Telix disclosed receiving a subpoena from the U.S. Securities and Exchange Commission regarding its disclosures on prostate cancer therapeutics, resulting in a more than 13% drop in its stock price over two trading sessions [5]. - On August 28, 2025, Telix revealed it received a Complete Response Letter from the FDA for its product TLX250-CDx, citing deficiencies in the Chemistry, Manufacturing, and Controls package, which led to a more than 21% decline in its stock price over two trading sessions [6]. Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Telix Pharmaceuticals securities during the Class Period to seek appointment as lead plaintiff in the class action lawsuit [7]. - The lead plaintiff represents the interests of all class members and can select a law firm to litigate the case [7]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [8]. - The firm has a strong track record, being ranked 1 in securing monetary relief for investors in securities class action cases [8].